|
Pathogen
|
Vaccine Envisaged
|
Target Populationa
|
|
Respiratory syncytial virus
|
Polypeptides produced by recombinant DNA technology
|
Infants at earliest possible age
|
|
|
Attenuated live virus
|
Infants at earliest possible age
|
|
Rotavirus
|
Attenuated high passage bovine RV
|
Infants at earliest possible age (preferably with oral polio vaccine)
|
|
|
Attenuated low passage bovine RV
|
Infants at earliest possible age (preferably with oral polio vaccine)
|
|
|
Rhesus monkey RV
|
Infants at earliest possible age (preferably with oral polio vaccine)
|
|
Salmonella typhi
|
Attenuated ga1E mutant S. typhi strain TY21a
|
Children; young adults at risk; travelers from developed countries to endemic areas
|
|
|
Aromatic amino acid dependent strains of S. typhi
|
Children; young adults at risk; travelers from developed countries to endemic areas
|
|
Shigella spp.
|
Probably plasmid mediated outer membrane protein invasion determinant (there are a small number of promising options needing investigation to determine best approach)
|
Infants at birth or earliest possible age; elderly for epidemic strains
|
|
Streptococcus A
|
Synthetic M protein segment (excluding portions cross-reacting with human tissue)
|
Children, <3–4 yrs
|
|
Streptococcus pneumoniae
|
Conjugated polysaccharides, polyvalent
|
Infants
|
|
Vibrio cholera
|
Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis
|
Children, esp. <2 yrs
|
|
|
Inactivated antigens
|
Children, esp. <2 yrs
|
|
Yellow fever virus
|
Attenuated live virus produced in cell culture
|
Young children
|
|
aCalculations of benefits are conducted assuming delivery at ages consistent with schedules of vaccinations recommended by the World Health Organization Expanded Program on Immunization (see Chapters 6 and 7).
|
